+1-510-404-8135
Advancement and innovation of new healthcare technologies such as next generation sequencing, high throughput screening (HTS), and Digital PCR are developing the platform for the growth of Pharmacogenomics (PGx) market. The global PGx market is expected to grow over $14.85 billion by 2022.
View Updated Report: Global Pharmacogenomics Market – Analysis and Forecast, 2019-2028
Rapid advancement and innovation of new healthcare technologies such as next generation sequencing, High Throughput Screening (HTS), and Digital Polymerase Chain Reaction (PCR) are further enhancing the platform for the growth of Pharmacogenomics (PGx) market. The completion of first human genome project in 1990s has created the platform for the development of further enhanced Pharmacogenomics solutions. PGx is not a modernized market but the increasing demand for precision medicine, targeted therapeutics and increasing cases of adverse drug reactions are some of the major factors which led to a tremendous growth rate in the past few years.
Since the announcement of ‘Precision Medicine Initiative’ by the President Barack Obama in January 2015, a large number of Research and Development (R&D) programs has been taken up for the developing precise drugs, targeted therapeutics, and laboratory tests which required Pharmacogenomics analysis. At present, government initiatives are focused towards launching a large number of PGx test & drugs, controlling the increasing level of genetic disorders, and integrating advanced technologies to fulfill the unmet needs of the patients. Most of the developments taking place in the present scenario are mainly related to oncology & cardiovascular diseases, but it is anticipated that it may target almost all therapeutic areas affected by genetic mutations.
Government regulations and standards are sustaining the growth and development of the PGx market. The main aim of these regulations is to make the PGx solutions more adaptable and focused toward oncology, pain management, CNS, CVD, and infectious diseases among others. The patients are benefitted indirectly by these regulations as it save time and cut-down cost as the patients get the required treatment for the specific disease. The market growth is propelled due to factors such as: rising usage in drug discovery processes, increasing demand for pharmacogenomics & precise drugs, technological innovation and advancement, increasing genetic disorder/abnormalities, and government support and regulations.
This study includes an overview and analysis of the PGx market, by type of ecosystem players ,type of therapeutics application, technology type, and geographical regions; allowing the researcher to develop a comprehensive outlook of the market. The PGx market report presents a detailed analysis of the key market dynamics and provides an extensive insight into various forms of developments, trends and key participants. All of the above mentioned report coverage parameters are discussed across different regions like North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW).
While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, compliances, and regulatory bodies, and their involvement in the PGx market. The research incorporates Porter’s Five Forces Model for in-depth analysis of the PGx market and an assessment of the factors governing the same.
| TABLE OF CONTENT | ||
| 1 | Report Overview | |
| 1.1 | Report Scope | |
| 1.1.1 | Report Coverage | |
| 1.1.2 | Assumptions And Limitations | |
| 1.1.3 | Market Classification & Segmentation | |
| 1.2 | Research Methodology | |
| 1.2.1 | Data Points Considered For Market Size Estimation | |
| 1.2.2 | Key Data Point Sources | |
| 1.2.2.1 | Key Data Points From Primary Sources | |
| 1.2.2.2 | Key Data Points From Secondary Sources | |
| 1.2.3 | Data Triangulation | |
| 1.2.4 | Top-Down Approach | |
| 1.2.5 | Bottom-Up Approach | |
| 1.3 | Report Description | |
| 2 | Executive Summary | |
| 2.1 | Global Market Scenario | |
| 3 | Market Overview | |
| 3.1 | Introduction | |
| 3.2 | Pharmacogenomics: Mechanism Of Action | |
| 3.3 | Role Of Companion Diagnostics In PGX | |
| 3.4 | Role Of Biomarkers In PGX | |
| 3.5 | Role Of Molecular Diagnostics In PGX | |
| 3.6 | Benefits Of PGX | |
| 3.7 | End-Use Applications Of PGX | |
| 3.8 | Market Dynamics | |
| 3.8.1 | Market Drivers | |
| 3.8.2 | Market Challenges | |
| 3.8.3 | Market Opportunities | |
| 4 | Competitive Insights | |
| 4.1 | Key Market Developments & Strategies | |
| 4.1.1 | Competitive Landscape Of Some Of The Key Players | |
| 4.1.2 | Partnerships, Joint Ventures And Collaborations | |
| 4.1.2.1 | Key Insights | |
| 4.1.2.2 | Recent Partnerships, Joint Ventures And Collaborations | |
| 4.1.3 | Product Launch And Developments | |
| 4.1.3.1 | Key Insights | |
| 4.1.3.2 | Recent Product Launch And Developments | |
| 4.1.4 | Patents, Licensing, Certification And Approvals | |
| 4.1.4.1 | Key Insights | |
| 4.1.4.2 | Recent Patents, Licensing, Certification And Approvals | |
| 4.1.5 | Mergers And Acquisitions | |
| 4.1.5.1 | Key Insights | |
| 4.1.5.2 | Recent Mergers And Acquisitions | |
| 4.1.6 | Business Contracts And Business Expansions | |
| 4.1.6.1 | Key Insights | |
| 4.1.6.2 | Recent Business Contracts And Business Expansions | |
| 4.1.7 | Other Strategies | |
| 4.1.7.1 | Key Insights | |
| 4.1.7.2 | Recent Developments Of Other Strategies | |
| 4.2 | Porter’s Five Forces Analysis | |
| 4.2.1 | Threat Of Substitutes | |
| 4.2.2 | Threat Of New Entrants | |
| 4.2.3 | Bargaining Power Of Buyers | |
| 4.2.4 | Bargaining Power Of Suppliers | |
| 4.2.5 | Intensity Of Competitive Rivalry | |
| 5 | Industry Analysis | |
| 5.1 | Patent Analysis | |
| 5.1.1 | Some Of The Key Players | |
| 5.1.2 | Others (University/Hospital/Person) | |
| 5.2 | Regulations, Consortiums, Certifications, & Standards | |
| 5.2.1 | Regulatory Bodies | |
| 5.2.2 | Examples Of Some Common Acts Certifications | |
| 5.3 | Value Chain Analysis | |
| 6 | Global Pharmacogenomics Market By Technology | |
| 6.1 | Market Segmentation By Technology | |
| 6.2 | Microarray | |
| 6.2.1 | Introduction | |
| 6.2.2 | Microarray: Types, Applications & Key Players | |
| 6.2.3 | Microarray: Market Dynamics & Recent Developments | |
| 6.3 | Sequencing | |
| 6.3.1 | Introduction | |
| 6.3.2 | Sequencing: Market Dynamics, Applications & Key Players | |
| 6.3.3 | Types Of Sequencing Technologies | |
| 6.3.3.1 | Sanger Sequencing | |
| 6.3.3.2 | Pyrosequencing | |
| 6.3.3.3 | Next-Gen Sequencing (NGS) | |
| 6.3.3.3.1 | Next-Gen Sequencing (NGS) Applications & Key Players | |
| 6.3.3.3.2 | Next-Gen Sequencing (NGS) Recent Developments | |
| 6.4 | Polymerase Chain Reaction (PCR) | |
| 6.4.1 | Introduction | |
| 6.4.2 | PCR Types | |
| 6.4.3 | PCR: Market Dynamics, Applications & Key Players | |
| 6.5 | Other Technologies | |
| 6.5.1 | Mass Spectrometry | |
| 6.5.2 | Electrophoresis | |
| 7 | Global Pharmacogenomics Market By Ecosystem Players | |
| 7.1 | PGX Ecosystem Players: Overview | |
| 7.2 | Market Segmentation By Ecosystem Players | |
| 7.2.1 | Market Insights & Statistics | |
| 7.3 | Diagnostic Test Companies | |
| 7.3.1 | Introduction | |
| 7.3.2 | Market Statistics | |
| 7.3.3 | Diagnostic Companies: Drivers & Challenges | |
| 7.3.4 | Recent Key Developments | |
| 7.3.5 | Key Players | |
| 7.4 | Pharmaceuticals Companies | |
| 7.4.1 | Introduction | |
| 7.4.2 | Market Statistics | |
| 7.4.3 | Drug Development Process | |
| 7.4.4 | Role Of Pharmaceutical Companies & Example Of Some Drugs | |
| 7.4.5 | Pharmaceuticals Companies: Drivers & Challenges | |
| 7.4.6 | Recent Key Developments | |
| 7.4.7 | Key Players | |
| 7.5 | Service Providers | |
| 7.5.1 | Introduction | |
| 7.5.2 | Market Statistics | |
| 7.5.3 | Service Provider: Roles & Big Data Benefits | |
| 7.5.4 | Big Data Companies: Drivers & Challenges | |
| 7.5.5 | Recent Key Developments | |
| 7.5.6 | Key Players | |
| 8 | Global Pharmacogenomics Market By Therapeutic Applications | |
| 8.1 | Market Segmentation | |
| 8.2 | Market Statistics | |
| 8.3 | Cancer/Oncology | |
| 8.3.1 | Key Insights & Statistics | |
| 8.3.2 | Market Statistics | |
| 8.3.3 | Types Of Cancer | |
| 8.3.4 | Cancer: Examples Of Some Drugs | |
| 8.3.5 | Cancer: Examples Of Some Tests | |
| 8.3.6 | Market Dynamics & Key Players | |
| 8.3.7 | Recent Key Developments | |
| 8.4 | Cardiovascular Diseases (CVD) | |
| 8.4.1 | Key Insights & Statistics | |
| 8.4.2 | Market Statistics | |
| 8.4.3 | CVD: Examples Of Some Drugs | |
| 8.4.4 | CVD: Examples Of Some Tests | |
| 8.4.5 | Recent Key Developments & Key Players | |
| 8.5 | Central Nervous System(CNS) | |
| 8.5.1 | Key Insights & Statistics | |
| 8.5.2 | Market Statistics | |
| 8.5.3 | CNS: Examples Of Some Drugs | |
| 8.5.4 | CNS: Examples Of Some Tests | |
| 8.5.5 | Recent Key Developments & Key Players | |
| 8.6 | Infectious Diseases | |
| 8.6.1 | Key Insights & Statistics | |
| 8.6.2 | Market Statistics | |
| 8.6.3 | Infectious Diseases : Examples Of Some Drugs | |
| 8.6.4 | Recent Key Developments & Key Players | |
| 8.7 | Other Diseases | |
| 8.7.1 | Key Insights & Statistics | |
| 8.7.2 | Market Statistics | |
| 8.7.3 | Other Diseases : Examples Of Some Drugs | |
| 8.7.4 | Other Diseases : Examples Of Some Tests | |
| 8.7.5 | Recent Key Developments & Key Players | |
| 9 | Global Pharmacogenomics Market By Geography | |
| 9.1 | Geographical Scenario | |
| 9.2 | Market Insights & Statistics | |
| 9.3 | North America | |
| 9.3.1 | Market Scope | |
| 9.3.2 | North America: Market Insights & Statistics | |
| 9.3.3 | North American Market Dynamics | |
| 9.3.4 | Key Regulatory Bodies & Associations | |
| 9.3.5 | The U.S. | |
| 9.3.5.1 | The U.S.: Market Statistics | |
| 9.3.5.2 | The U.S.: Key Insights | |
| 9.3.6 | Canada | |
| 9.3.7 | Recent Key Developments | |
| 9.4 | Europe | |
| 9.4.1 | Market Scope | |
| 9.4.2 | Europe: Market Insights & Statistics | |
| 9.4.3 | European Market Dynamics | |
| 9.4.4 | Key Regulatory Bodies & Associations | |
| 9.4.5 | The U.K. | |
| 9.4.6 | Germany | |
| 9.4.7 | Recent Key Developments | |
| 9.5 | Asia-Pacific (APAC) | |
| 9.5.1 | Market Scope | |
| 9.5.2 | APAC: Market Insights & Statistics | |
| 9.5.3 | APAC Market Dynamics | |
| 9.5.4 | China | |
| 9.5.5 | Japan | |
| 9.5.6 | India | |
| 9.5.7 | Recent Key Developments | |
| 9.6 | Rest Of The World (ROW) | |
| 9.6.1 | ROW: Market Insights & Statistics | |
| 9.6.2 | Middle East | |
| 9.6.3 | South America | |
| 9.6.4 | Africa | |
| 9.6.5 | Recent Key Development | |
| 10 | Company Overview | |
| 10.1 | Abbott Laboratories | |
| 10.1.1 | Overview | |
| 10.1.2 | Financials | |
| 10.1.3 | Financial Summary | |
| 10.1.4 | Key Developments | |
| 10.1.5 | SWOT Analysis | |
| 10.2 | Affymetrix, Inc. | |
| 10.2.1 | Overview | |
| 10.2.2 | Financials | |
| 10.2.3 | Financial Summary | |
| 10.2.4 | Key Developments | |
| 10.2.5 | SWOT Analysis | |
| 10.3 | Assurex Health, Inc. | |
| 10.3.1 | Overview | |
| 10.3.2 | Key Developments | |
| 10.3.3 | SWOT Analysis | |
| 10.4 | Astrazeneca | |
| 10.4.1 | Overview | |
| 10.4.2 | Financials | |
| 10.4.3 | Financial Summary | |
| 10.4.4 | Key Developments | |
| 10.4.5 | SWOT Analysis | |
| 10.5 | Illumina, Inc. | |
| 10.5.1 | Overview | |
| 10.5.2 | Financials | |
| 10.5.3 | Financial Summary | |
| 10.5.4 | Key Developments | |
| 10.5.5 | SWOT Analysis | |
| 10.6 | Laboratory Corporation Of America Holdings | |
| 10.6.1 | Overview | |
| 10.6.2 | Financials & Financial Summary | |
| 10.6.3 | Key Developments | |
| 10.6.4 | SWOT Analysis | |
| 10.7 | Myriad Genetics, Inc. | |
| 10.7.1 | Overview | |
| 10.7.2 | Financials & Financial Summary | |
| 10.7.3 | Key Developments | |
| 10.7.4 | SWOT Analysis | |
| 10.8 | Pfizer, Inc. | |
| 10.8.1 | Overview | |
| 10.8.2 | Financials | |
| 10.8.3 | Financial Summary | |
| 10.8.4 | Key Developments | |
| 10.8.5 | SWOT Analysis | |
| 10.9 | Qiagen, Inc. | |
| 10.9.1 | Overview | |
| 10.9.2 | Financials | |
| 10.9.3 | Financial Summary | |
| 10.9.4 | Key Developments | |
| 10.9.5 | SWOT Analysis | |
| 10.10 | Roche Holding AG-BR | |
| 10.10.1 | Overview | |
| 10.10.2 | Financials | |
| 10.10.3 | Financial Summary | |
| 10.10.4 | Key Developments | |
| 10.10.5 | SWOT Analysis | |
| 10.11 | TEVA Pharmaceutical Industries Ltd. | |
| 10.11.1 | Overview | |
| 10.11.2 | Financials | |
| 10.11.3 | Financial Summary | |
| 10.11.4 | Key Developments | |
| 10.11.5 | SWOT Analysis | |
| 10.12 | Thermo Fisher Scientific | |
| 10.12.1 | Overview | |
| 10.12.2 | Financials | |
| 10.12.3 | Financial Summary | |
| 10.12.4 | Key Developments | |
| 10.12.5 | SWOT Analysis | |
| 10.13 | Transgenomic, Inc. | |
| 10.13.1 | Overview | |
| 10.13.2 | Financials & Financial Summary | |
| 10.13.3 | Key Developments | |
| 10.13.4 | SWOT Analysis | |
| 10.14 | Other Emerging Companies | |
| 10.14.1 | Diagnostic Test Companies | |
| 10.14.1.1 | Companiondx Reference Lab, LLC | |
| 10.14.1.2 | Mapmy Genome | |
| 10.14.1.3 | Asuragen | |
| 10.14.1.4 | 23andme | |
| 10.14.1.5 | Cnsdose | |
| 10.14.2 | Pharmaceutical Companies | |
| 10.14.2.1 | Actinium Pharmaceuticals, Inc | |
| 10.14.2.2 | Foundation Medicine | |
| 10.14.3 | Service Providers | |
| 10.14.3.1 | PGX Software LLC | |
| 10.14.3.2 | Gene Logic | |
| 10.14.3.3 | Genewiz | |
| 10.14.3.4 | Conatus Consulting, LLC | |
| 10.14.4 | Care Providers | |
| 10.14.4.1 | Gene DX | |
| 10.14.4.2 | Mayo Clinic | |
| 11 | List Of Acronyms | |
| List Of Figures | ||
| 1 | Year Consideration | |
| 2 | Market Classification & Segmentation | |
| 3 | Research Methodology | |
| 4 | Global Pharmacogenomics Market ($Billion) | |
| 5 | Global Pharmacogenomics Market Value, 2015-2022 ($Billion) | |
| 6 | Global PGX Market, By Ecosystem, 2015-2022 ($Billion) | |
| 7 | Global PGX Market Share, By Therapeutic Application, 2015-2022 ($Billion) | |
| 8 | Global Pharmacogenomics Market, By Geography-2022 | |
| 9 | Mechanism Of Action | |
| 10 | Role Of Companion Diagnostics In PGX | |
| 11 | Role Of Biomakers In PGX | |
| 12 | Role Of Molecular Diagnostics IN PGX | |
| 13 | Benefits Of PGX | |
| 14 | End-Use Applications Of PGX | |
| 15 | Market Dynamics | |
| 16 | Partnerships, Joint Ventures And Collaborations: Key Players Analysis | |
| 17 | Product Launch And Developments: Key Players Analysis | |
| 18 | Patents, Licensing, Certification And Approvals : Key Players Analysis | |
| 19 | Mergers And Acquisitions: Key Players Analysis | |
| 20 | Business Contracts And Business Expansions : Key Players Analysis | |
| 21 | Others Strategies: Key Players Analysis | |
| 22 | Porter’s Five Forces Analysis | |
| 23 | Threat Of Substitutes | |
| 24 | Threat Of New Entrants | |
| 25 | Bargaining Power Of Buyers | |
| 26 | Bargaining Power Of Suppliers | |
| 27 | Intensity Of Competitive Rivalry | |
| 28 | Roles And Responsibilities Of Healthcare Policy Makers | |
| 29 | Role Of FDA In PGX | |
| 30 | Classification Of Medical Devices | |
| 31 | Examples Of Some Common Acts | |
| 32 | Example Of Some Certifications | |
| 33 | Value Chain Analysis | |
| 34 | Example Of Some Significant Players In PGX Value Chain | |
| 35 | Generalized Process For The Microarray | |
| 36 | Different Types Of Microarrays | |
| 37 | Applications Of Microarrays | |
| 38 | Microarray- Drivers & Challenges | |
| 39 | Sequencing Technologies In PGX | |
| 40 | Sequencing - Drivers & Challenges | |
| 41 | Applications Of Sequencing | |
| 42 | NGS- Drivers & Challenges | |
| 43 | Applications Of NGS | |
| 44 | Generalized Process For PCR | |
| 45 | Different Types Of PCR | |
| 46 | PCR - Drivers & Challenges | |
| 47 | Applications Of PCR | |
| 48 | Applications Of Mass Spectrometry | |
| 49 | Applications Of Electrophoresis | |
| 50 | Overview Of PGX Ecosystem Players | |
| 51 | Global PGX Market By Ecosystem Players | |
| 52 | Global Pharmacogenomics Market, By Ecosystem , 2015-2022 ($Billion) | |
| 53 | Global PGX Ecosystem Market, By Diagnostic Tests Companies, 2015-2022 ($Billion) | |
| 54 | Global PGX Diagnostic Tests Market, By Therapeutic Applications, 2015-2022 ($Billion) | |
| 55 | Global PGX Diagnostic Tests Market, By Geography, 2015-2022 ($Billion) | |
| 56 | Diagnostic Companies- Drivers & Challenges | |
| 57 | Global PGX Ecosystem Market, By Pharmaceutical Companies, 2015-2022 ($Billion) | |
| 58 | Global PGX Pharmaceutical Market, By Therapeutic Applications, 2015-2022 ($Billion) | |
| 59 | Global PGX Pharmaceutical Market, By Geography, 2015-2022 ($Billion) | |
| 60 | Drug Development Process | |
| 61 | Role Of Pharmaceuticals Companies | |
| 62 | Pharmaceuticals Companies- Drivers & Challenges | |
| 63 | Global PGX Ecosystem Market, By Service Providers, 2015-2022 ($Billion) | |
| 64 | Global PGX Service Providers Market, By Therapeutic Applications, 2015-2022 ($Billion) | |
| 65 | Global PGX Service Providers Market, By Geography, 2015-2022 ($Billion) | |
| 66 | Three Data Drivers Of PGX Market | |
| 67 | Benefits Of Big Data | |
| 68 | Big Data Companies- Drivers & Challenges | |
| 69 | Global PGX Market By Therapeutics Applications | |
| 70 | Global PGX Market, By Theraeutics Application, 2015-2022 ($Billion) | |
| 71 | Global PGX Market By Oncology,2015-2022($Billion) | |
| 72 | Global PGX Oncology Market, By Ecosystem, 2015-2022 ($Billion) | |
| 73 | Global PGX Oncology Market, By Geography, 2015-2022 ($Billion) | |
| 74 | Types Of Cancer | |
| 75 | Oncology Market Dynamics | |
| 76 | Global PGX Market By CVD, 2015-2022 ($Billion) | |
| 77 | Global PGX CVD Market, By Ecosystem, 2015-2022 ($Billion) | |
| 78 | Global PGX CVD Market, By Geography, 2015-2022 ($Billion) | |
| 79 | Global PGX Market By CNS, 2015-2022 ($Billion) | |
| 80 | Global PGX CNS Market, By Ecosystem, 2015-2022 ($Billion) | |
| 81 | Global PGX CNS Market, By Geography, 2015-2022 ($Billion) | |
| 82 | Global PGX Market By Infectious Diseases, 2015-2022 ($Billion) | |
| 83 | Global PGX Infectious Diseases Market, By Ecosystem, 2015-2022 ($Billion) | |
| 84 | Global PGX Infectious Diseases Market, By Geography, 2015-2022 ($Billion) | |
| 85 | Global PGX Market By Other Diseases, 2015-2022 ($Billion) | |
| 86 | Global PGX Other Diseases Market, By Ecosystem, 2015-2022 ($Billion) | |
| 87 | Global PGX Other Diseases Market, By Geography, 2015-2022 ($Billion) | |
| 88 | Growth Trajectory Of PGX Market | |
| 89 | Global Pharmacogenomics Market, By Geography , 2015-2022 ($Billion) | |
| 90 | Global Pharmacogenomics Market, By Geography (2015) | |
| 91 | North American PGX Market, 2015 | |
| 92 | North American PGX Market, 2015-2022 ($Billion) | |
| 93 | North American Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) | |
| 94 | North American Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion) | |
| 95 | North American Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion) | |
| 96 | North American Market Dynamics | |
| 97 | Key Regulatory Bodies & Associations | |
| 98 | The U.S. PGX Market, 2015-2022 ($Billion) | |
| 99 | The U.S. Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion) | |
| 100 | The U.S. Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion) | |
| 101 | Canada PGX Market Dynamics | |
| 102 | European PGX Market, 2015 | |
| 103 | European PGX Market,2015-2022($Billion) | |
| 104 | European Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) | |
| 105 | European Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion) | |
| 106 | European Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion) | |
| 107 | European Market Dynamics | |
| 108 | Key Regulatory Bodies & Associations | |
| 109 | The U.K. PGX Market, 2015-2022 ($Billion) | |
| 110 | The Germany PGX Market, 2015-2022 ($Billion) | |
| 111 | APAC Country-Wise CAGR Of PGX Market | |
| 112 | APAC PGX Market, 2015-2022 ($Billion) | |
| 113 | APAC Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) | |
| 114 | APAC Pharmacogenomics MARKET,BY Ecosystem, 2015-2022 ($Billion) | |
| 115 | APAC Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion) | |
| 116 | APAC Market Dynamics | |
| 117 | The China PGX Market, 2015-2022 ($Billion) | |
| 118 | China Market Dynamics | |
| 119 | The Japan PGX Market, 2015-2022 ($Billion) | |
| 120 | The Indian PGX Market, 2015-2022 ($Billion) | |
| 121 | Indian Market Dynamics | |
| 122 | Region-Wise CAGR Of PGX Market | |
| 123 | ROW PGX Market, 2015-2022 ($Billion) | |
| 124 | ROW PGX Market, By Sub-Region, 2015-2022 ($Billion) | |
| 125 | ROW PGX Market, By Ecosystem, 2015-2022 ($Billion) | |
| 126 | ROW PGX Market, By Therapeutics, 2015-2022 ($Billion) | |
| 127 | Middle East PGX Market, 2015-2022 ($Billion) | |
| 128 | South American PGX Market, 2015-2022 ($Billion) | |
| 129 | African PGX Market, 2015-2022 ($Billion) | |
| 130 | : Abbott Laboratories, Inc.– Overall Financials, 2013-2015 ($Billion) | |
| 131 | Abbott Laboratories, Inc.- Financials By Business Segments, 2013-2015 ($Billion) | |
| 132 | Abbott Laboratories, Inc.– Financials By Geography, 2013-2015 ($Billion) | |
| 133 | Abbott Laboratories, Inc.- SWOT Analysis | |
| 134 | Affymetrix, Inc.– Overall Financials, 2013-2015 ($Million) | |
| 135 | Affymetrix, Inc.- Financials By Business Segments, 2013-2015 ($Million) | |
| 136 | Affymetrix, Inc.– Financials By Geography,2013-2015 ($Million) | |
| 137 | Affymetrix, Inc.- SWOT Analysis | |
| 138 | Assurex Health, Inc.- SWOT Analysis | |
| 139 | Astrazeneca – Overall Financials, 2013-2015 ($Billion) | |
| 140 | Astrazeneca- Financials By Business Segments, 2013-2015 ($Billion) | |
| 141 | Astrazeneca– Financials By Geography,2013-2015 ($Billion) | |
| 142 | Astrazeneca- SWOT Analysis | |
| 143 | Illumina, Inc.– Overall Financials, 2013-2015 ($Million) | |
| 144 | Illumina, Inc.- Financials By Business Segments, 2013-2015 ($Million) | |
| 145 | Illumina, Inc.– Financials By Geography, 2013-2015 ($Million) | |
| 146 | Illumina, Inc.- SWOT Analysis | |
| 147 | Laboratory Corporation Of America Holding.- Overall Financials, 2013-2015 ($Million) | |
| 148 | Laboratory Corporation Of America Holding—Financials By Business Segments, 2013-2015 ($ Million) | |
| 149 | Laboratory Corporation Of America Holding.- SWOT analysis | |
| 150 | Myriad Genetics, Inc.– Overall Financials, 2013-2015 ($Million) | |
| 151 | Myriad Genetics, Inc.– Financials By Business Segments, 2013-2015 ($Million) | |
| 152 | Myriad Genetics,INC.- SWOT Analysis | |
| 153 | Pfizer, Inc.– Overall Financials, 2013-2015 ($Billion) | |
| 154 | Pfizer,Inc. – Financials By Geography ,2013-2015 ($Billion) | |
| 155 | Pfizer, Inc.- Financials By Business Segments, 2014-2015 ($Billion) | |
| 156 | Pfizer, Inc.– Financials By Business Segment, 2013 | |
| 157 | Pfizer, Inc.- SWOT analysis | |
| 158 | Qiagen– Overall Financials, 2013-2015 ($Million) | |
| 159 | Qiagen- Financials By Business Segments, 2013-2015 ($Million) | |
| 160 | Qiagen– Financials By Geography, 2013-2015 ($Million) | |
| 161 | Qiagen- SWOT Analysis | |
| 162 | Roche Holding– Overall Financials,2013-2015 ($Billion) | |
| 163 | Roche Holding- Financials By Business Segments, 2013-2015 ($Billion) | |
| 164 | Roche Holding– Financials Of Diagnostics Division By Geography, 2013-2015 ($Billion) | |
| 165 | Roche Holding– Financials Of Pharmaceuticals,SEGMENT By Geography, 2013-2015 ($Billion) | |
| 166 | Roche Holding- SWOT Analysis | |
| 167 | TEVA Pharmaceutical Ltd.– Overall Financials, 2013-2015 ($Billion) | |
| 168 | TEVA Pharmaceutical Ltd.- Financials By Business Segments, 2013-2015 ($Billion) | |
| 169 | TEVA Pharmaceutical Ltd.– Financials By Geography, 2013-2015 ($Billion) | |
| 170 | TEVA Pharmaceutical Industries Ltd.- SWOT analysis | |
| 171 | Thermo Fisher, Inc.- Overall Financials, 2013-2015 ($Billion) | |
| 172 | Thermo Fisher, Inc.— Financials By Business Segments, 2013-2015 ($Billion) | |
| 173 | Thermo Fisher, Inc.— Financials By Geography, 2013-2015 ($Billion) | |
| 174 | Thermo Fisher Scientific, Inc.- SWOT Analysis | |
| 175 | Transgenomic, Inc.- Overall Financials,2013-2015 ($Million) | |
| 176 | Transgenomic, Inc.- Financials By Business SEGEMENTS, 2013-2015 ($Million) | |
| 177 | Transgenomic, Inc.- SWOT Analysis | |
| List of Tables | ||
| 1 | Competitive Landscape: Some Of The Key Players | |
| 2 | Recent Partnerships, Joint Ventures And Collaborations | |
| 3 | Recent Product Launch And Developments | |
| 4 | Recent Patents, Licensing, Certification And Approvals | |
| 5 | Recent Mergers And Acquisitions | |
| 6 | Recent Business Contracts And Business Expansions | |
| 7 | Recent Developments Of Other Strategies | |
| 8 | Patent Analysis Of Some Key Players | |
| 9 | Patent Analysis Of Some University/Hospital/Person | |
| 10 | Microarray- Recent Key Developments | |
| 11 | NGS- Recent Key Developments | |
| 12 | Difference Between Realt Time & Digital PCR | |
| 13 | Diagnostic Test Companies- Recent Key Developments | |
| 14 | Example Of Some Pharmacogenomic Drugs | |
| 15 | Pharmaceuticals Companies- Recent Key Developments | |
| 16 | Service Providers- Recent Key Developments | |
| 17 | Cancer- Examples Of Some Drugs | |
| 18 | Cancer- Examples Of Some Tests | |
| 19 | Oncology- Recent Key Developments | |
| 20 | CVD- Examples Of Some Drugs | |
| 21 | CVD- Examples Of Some Tests | |
| 22 | CNS- Examples Of Some Drugs | |
| 23 | CNS- Examples Of Some Tests | |
| 24 | Infectious Diseases- Examples Of Some Drugs | |
| 25 | Other Diseases- Examples Of Some Drugs | |
| 26 | North American Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) | |
| 27 | North American Pharmacogenomics Market Recent Key Dvelopments | |
| 28 | European Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) | |
| 29 | European PGX Market Recent Key Developments | |
| 30 | APAC Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) | |
| 31 | APAC Pharmacogenomics Market Recent Key Developments | |
| 32 | ROW Pharmacogenomics Market,By Sub-Region, 2015-2022 | |
| 33 | ROW Recent Key Development | |
| 34 | Abbott Laboratories, Inc. Recent Developments | |
| 35 | Affymetrix, Inc. Recent Developments | |
| 36 | Assurex Health, Inc. Recent Developments | |
| 37 | Astrazeneca Recent Developments | |
| 38 | Illumina, Inc. Recent Developments | |
| 39 | Laboratory Corporation Of America Holding Recent Developments | |
| 40 | Myriad Genetics Recent Developments | |
| 41 | Pfizer, Inc. Recent Developments | |
| 42 | Qiagen Recent Developments | |
| 43 | Roche Holding Recent Developments | |
| 44 | TEVA Pharmaceutical Industries Ltd. Recent Developments | |
| 45 | Thermo Fisher, Inc. Recent Developments | |
| 46 | Transgenomic, Inc. Recent Developments | |
The global Pharmacogenomics (PGx) market growth is gradually gaining speed as large number of government initiatives and research & development programs have been launched in the last few years.Advancement and innovation of new healthcare technologies such as next generation sequencing, high throughput screening (HTS), and Digital PCR are developing the platform for the growth of Pharmacogenomics (PGx) market. The global PGx market is expected to grow over $14.85 billion by 2022.
The market growth is propelled due to factors such as: rising usage in drug discovery processes, increasing demand for pharmacogenomics & precise drugs, technological innovation and advancement, increasing genetic disorders/abnormalities, and government support and regulations.The report has been further classified on the basis of ecosystem players, therapeutic applications, and geographical regions. Ecosystem is further segmented into: Pharmaceuticals companies, Diagnostic Companies, and Service Providers which includes Software & Healthcare database providers, Hospitals & Care Providers and Insurance Providers.
Diagnostic Test segment is holding the maximum market share and is expected to grow at 11.63% CAGR from 2016 to 2022. This is due to the increasing demand for diagnostic tests as patients are emphasizing more on pre-diagnosis treatment, increasing genetic disorders & mutational diseases, and government initiatives and investment in research and development programs among others.
In North America, existing players are integrating with new start-ups through partnerships and collaboration to capture the North American segment. North American local players are entering in other developing regions to capture more market share. Throughout the Asia-Pacific and European countries, regulatory bodies are rolling out regulations to keep a check on latest technologies.
North America is the largest contributor in the revenue generation in PGx market followed by Europe region, and is expected to grow at a high CAGR of 12.14% CAGR from 2016 to 2022. APAC region is expected to show the fastest growth globally, and is expected to grow at 18.74% CAGR from 2016 to 2022.
The APAC region is focusing more on technological development and introduction of new gene sequencing and gene mapping tools into healthcare systems to develop specific laboratory diagnostic tests.
We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.
With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.
Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.
View Updated Report: Global Pharmacogenomics Market – Analysis and Forecast, 2019-2028
Rapid advancement and innovation of new healthcare technologies such as next generation sequencing, High Throughput Screening (HTS), and Digital Polymerase Chain Reaction (PCR) are further enhancing the platform for the growth of Pharmacogenomics (PGx) market. The completion of first human genome project in 1990s has created the platform for the development of further enhanced Pharmacogenomics solutions. PGx is not a modernized market but the increasing demand for precision medicine, targeted therapeutics and increasing cases of adverse drug reactions are some of the major factors which led to a tremendous growth rate in the past few years.
Since the announcement of ‘Precision Medicine Initiative’ by the President Barack Obama in January 2015, a large number of Research and Development (R&D) programs has been taken up for the developing precise drugs, targeted therapeutics, and laboratory tests which required Pharmacogenomics analysis. At present, government initiatives are focused towards launching a large number of PGx test & drugs, controlling the increasing level of genetic disorders, and integrating advanced technologies to fulfill the unmet needs of the patients. Most of the developments taking place in the present scenario are mainly related to oncology & cardiovascular diseases, but it is anticipated that it may target almost all therapeutic areas affected by genetic mutations.
Government regulations and standards are sustaining the growth and development of the PGx market. The main aim of these regulations is to make the PGx solutions more adaptable and focused toward oncology, pain management, CNS, CVD, and infectious diseases among others. The patients are benefitted indirectly by these regulations as it save time and cut-down cost as the patients get the required treatment for the specific disease. The market growth is propelled due to factors such as: rising usage in drug discovery processes, increasing demand for pharmacogenomics & precise drugs, technological innovation and advancement, increasing genetic disorder/abnormalities, and government support and regulations.
This study includes an overview and analysis of the PGx market, by type of ecosystem players ,type of therapeutics application, technology type, and geographical regions; allowing the researcher to develop a comprehensive outlook of the market. The PGx market report presents a detailed analysis of the key market dynamics and provides an extensive insight into various forms of developments, trends and key participants. All of the above mentioned report coverage parameters are discussed across different regions like North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW).
While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, compliances, and regulatory bodies, and their involvement in the PGx market. The research incorporates Porter’s Five Forces Model for in-depth analysis of the PGx market and an assessment of the factors governing the same.
| TABLE OF CONTENT | ||
| 1 | Report Overview | |
| 1.1 | Report Scope | |
| 1.1.1 | Report Coverage | |
| 1.1.2 | Assumptions And Limitations | |
| 1.1.3 | Market Classification & Segmentation | |
| 1.2 | Research Methodology | |
| 1.2.1 | Data Points Considered For Market Size Estimation | |
| 1.2.2 | Key Data Point Sources | |
| 1.2.2.1 | Key Data Points From Primary Sources | |
| 1.2.2.2 | Key Data Points From Secondary Sources | |
| 1.2.3 | Data Triangulation | |
| 1.2.4 | Top-Down Approach | |
| 1.2.5 | Bottom-Up Approach | |
| 1.3 | Report Description | |
| 2 | Executive Summary | |
| 2.1 | Global Market Scenario | |
| 3 | Market Overview | |
| 3.1 | Introduction | |
| 3.2 | Pharmacogenomics: Mechanism Of Action | |
| 3.3 | Role Of Companion Diagnostics In PGX | |
| 3.4 | Role Of Biomarkers In PGX | |
| 3.5 | Role Of Molecular Diagnostics In PGX | |
| 3.6 | Benefits Of PGX | |
| 3.7 | End-Use Applications Of PGX | |
| 3.8 | Market Dynamics | |
| 3.8.1 | Market Drivers | |
| 3.8.2 | Market Challenges | |
| 3.8.3 | Market Opportunities | |
| 4 | Competitive Insights | |
| 4.1 | Key Market Developments & Strategies | |
| 4.1.1 | Competitive Landscape Of Some Of The Key Players | |
| 4.1.2 | Partnerships, Joint Ventures And Collaborations | |
| 4.1.2.1 | Key Insights | |
| 4.1.2.2 | Recent Partnerships, Joint Ventures And Collaborations | |
| 4.1.3 | Product Launch And Developments | |
| 4.1.3.1 | Key Insights | |
| 4.1.3.2 | Recent Product Launch And Developments | |
| 4.1.4 | Patents, Licensing, Certification And Approvals | |
| 4.1.4.1 | Key Insights | |
| 4.1.4.2 | Recent Patents, Licensing, Certification And Approvals | |
| 4.1.5 | Mergers And Acquisitions | |
| 4.1.5.1 | Key Insights | |
| 4.1.5.2 | Recent Mergers And Acquisitions | |
| 4.1.6 | Business Contracts And Business Expansions | |
| 4.1.6.1 | Key Insights | |
| 4.1.6.2 | Recent Business Contracts And Business Expansions | |
| 4.1.7 | Other Strategies | |
| 4.1.7.1 | Key Insights | |
| 4.1.7.2 | Recent Developments Of Other Strategies | |
| 4.2 | Porter’s Five Forces Analysis | |
| 4.2.1 | Threat Of Substitutes | |
| 4.2.2 | Threat Of New Entrants | |
| 4.2.3 | Bargaining Power Of Buyers | |
| 4.2.4 | Bargaining Power Of Suppliers | |
| 4.2.5 | Intensity Of Competitive Rivalry | |
| 5 | Industry Analysis | |
| 5.1 | Patent Analysis | |
| 5.1.1 | Some Of The Key Players | |
| 5.1.2 | Others (University/Hospital/Person) | |
| 5.2 | Regulations, Consortiums, Certifications, & Standards | |
| 5.2.1 | Regulatory Bodies | |
| 5.2.2 | Examples Of Some Common Acts Certifications | |
| 5.3 | Value Chain Analysis | |
| 6 | Global Pharmacogenomics Market By Technology | |
| 6.1 | Market Segmentation By Technology | |
| 6.2 | Microarray | |
| 6.2.1 | Introduction | |
| 6.2.2 | Microarray: Types, Applications & Key Players | |
| 6.2.3 | Microarray: Market Dynamics & Recent Developments | |
| 6.3 | Sequencing | |
| 6.3.1 | Introduction | |
| 6.3.2 | Sequencing: Market Dynamics, Applications & Key Players | |
| 6.3.3 | Types Of Sequencing Technologies | |
| 6.3.3.1 | Sanger Sequencing | |
| 6.3.3.2 | Pyrosequencing | |
| 6.3.3.3 | Next-Gen Sequencing (NGS) | |
| 6.3.3.3.1 | Next-Gen Sequencing (NGS) Applications & Key Players | |
| 6.3.3.3.2 | Next-Gen Sequencing (NGS) Recent Developments | |
| 6.4 | Polymerase Chain Reaction (PCR) | |
| 6.4.1 | Introduction | |
| 6.4.2 | PCR Types | |
| 6.4.3 | PCR: Market Dynamics, Applications & Key Players | |
| 6.5 | Other Technologies | |
| 6.5.1 | Mass Spectrometry | |
| 6.5.2 | Electrophoresis | |
| 7 | Global Pharmacogenomics Market By Ecosystem Players | |
| 7.1 | PGX Ecosystem Players: Overview | |
| 7.2 | Market Segmentation By Ecosystem Players | |
| 7.2.1 | Market Insights & Statistics | |
| 7.3 | Diagnostic Test Companies | |
| 7.3.1 | Introduction | |
| 7.3.2 | Market Statistics | |
| 7.3.3 | Diagnostic Companies: Drivers & Challenges | |
| 7.3.4 | Recent Key Developments | |
| 7.3.5 | Key Players | |
| 7.4 | Pharmaceuticals Companies | |
| 7.4.1 | Introduction | |
| 7.4.2 | Market Statistics | |
| 7.4.3 | Drug Development Process | |
| 7.4.4 | Role Of Pharmaceutical Companies & Example Of Some Drugs | |
| 7.4.5 | Pharmaceuticals Companies: Drivers & Challenges | |
| 7.4.6 | Recent Key Developments | |
| 7.4.7 | Key Players | |
| 7.5 | Service Providers | |
| 7.5.1 | Introduction | |
| 7.5.2 | Market Statistics | |
| 7.5.3 | Service Provider: Roles & Big Data Benefits | |
| 7.5.4 | Big Data Companies: Drivers & Challenges | |
| 7.5.5 | Recent Key Developments | |
| 7.5.6 | Key Players | |
| 8 | Global Pharmacogenomics Market By Therapeutic Applications | |
| 8.1 | Market Segmentation | |
| 8.2 | Market Statistics | |
| 8.3 | Cancer/Oncology | |
| 8.3.1 | Key Insights & Statistics | |
| 8.3.2 | Market Statistics | |
| 8.3.3 | Types Of Cancer | |
| 8.3.4 | Cancer: Examples Of Some Drugs | |
| 8.3.5 | Cancer: Examples Of Some Tests | |
| 8.3.6 | Market Dynamics & Key Players | |
| 8.3.7 | Recent Key Developments | |
| 8.4 | Cardiovascular Diseases (CVD) | |
| 8.4.1 | Key Insights & Statistics | |
| 8.4.2 | Market Statistics | |
| 8.4.3 | CVD: Examples Of Some Drugs | |
| 8.4.4 | CVD: Examples Of Some Tests | |
| 8.4.5 | Recent Key Developments & Key Players | |
| 8.5 | Central Nervous System(CNS) | |
| 8.5.1 | Key Insights & Statistics | |
| 8.5.2 | Market Statistics | |
| 8.5.3 | CNS: Examples Of Some Drugs | |
| 8.5.4 | CNS: Examples Of Some Tests | |
| 8.5.5 | Recent Key Developments & Key Players | |
| 8.6 | Infectious Diseases | |
| 8.6.1 | Key Insights & Statistics | |
| 8.6.2 | Market Statistics | |
| 8.6.3 | Infectious Diseases : Examples Of Some Drugs | |
| 8.6.4 | Recent Key Developments & Key Players | |
| 8.7 | Other Diseases | |
| 8.7.1 | Key Insights & Statistics | |
| 8.7.2 | Market Statistics | |
| 8.7.3 | Other Diseases : Examples Of Some Drugs | |
| 8.7.4 | Other Diseases : Examples Of Some Tests | |
| 8.7.5 | Recent Key Developments & Key Players | |
| 9 | Global Pharmacogenomics Market By Geography | |
| 9.1 | Geographical Scenario | |
| 9.2 | Market Insights & Statistics | |
| 9.3 | North America | |
| 9.3.1 | Market Scope | |
| 9.3.2 | North America: Market Insights & Statistics | |
| 9.3.3 | North American Market Dynamics | |
| 9.3.4 | Key Regulatory Bodies & Associations | |
| 9.3.5 | The U.S. | |
| 9.3.5.1 | The U.S.: Market Statistics | |
| 9.3.5.2 | The U.S.: Key Insights | |
| 9.3.6 | Canada | |
| 9.3.7 | Recent Key Developments | |
| 9.4 | Europe | |
| 9.4.1 | Market Scope | |
| 9.4.2 | Europe: Market Insights & Statistics | |
| 9.4.3 | European Market Dynamics | |
| 9.4.4 | Key Regulatory Bodies & Associations | |
| 9.4.5 | The U.K. | |
| 9.4.6 | Germany | |
| 9.4.7 | Recent Key Developments | |
| 9.5 | Asia-Pacific (APAC) | |
| 9.5.1 | Market Scope | |
| 9.5.2 | APAC: Market Insights & Statistics | |
| 9.5.3 | APAC Market Dynamics | |
| 9.5.4 | China | |
| 9.5.5 | Japan | |
| 9.5.6 | India | |
| 9.5.7 | Recent Key Developments | |
| 9.6 | Rest Of The World (ROW) | |
| 9.6.1 | ROW: Market Insights & Statistics | |
| 9.6.2 | Middle East | |
| 9.6.3 | South America | |
| 9.6.4 | Africa | |
| 9.6.5 | Recent Key Development | |
| 10 | Company Overview | |
| 10.1 | Abbott Laboratories | |
| 10.1.1 | Overview | |
| 10.1.2 | Financials | |
| 10.1.3 | Financial Summary | |
| 10.1.4 | Key Developments | |
| 10.1.5 | SWOT Analysis | |
| 10.2 | Affymetrix, Inc. | |
| 10.2.1 | Overview | |
| 10.2.2 | Financials | |
| 10.2.3 | Financial Summary | |
| 10.2.4 | Key Developments | |
| 10.2.5 | SWOT Analysis | |
| 10.3 | Assurex Health, Inc. | |
| 10.3.1 | Overview | |
| 10.3.2 | Key Developments | |
| 10.3.3 | SWOT Analysis | |
| 10.4 | Astrazeneca | |
| 10.4.1 | Overview | |
| 10.4.2 | Financials | |
| 10.4.3 | Financial Summary | |
| 10.4.4 | Key Developments | |
| 10.4.5 | SWOT Analysis | |
| 10.5 | Illumina, Inc. | |
| 10.5.1 | Overview | |
| 10.5.2 | Financials | |
| 10.5.3 | Financial Summary | |
| 10.5.4 | Key Developments | |
| 10.5.5 | SWOT Analysis | |
| 10.6 | Laboratory Corporation Of America Holdings | |
| 10.6.1 | Overview | |
| 10.6.2 | Financials & Financial Summary | |
| 10.6.3 | Key Developments | |
| 10.6.4 | SWOT Analysis | |
| 10.7 | Myriad Genetics, Inc. | |
| 10.7.1 | Overview | |
| 10.7.2 | Financials & Financial Summary | |
| 10.7.3 | Key Developments | |
| 10.7.4 | SWOT Analysis | |
| 10.8 | Pfizer, Inc. | |
| 10.8.1 | Overview | |
| 10.8.2 | Financials | |
| 10.8.3 | Financial Summary | |
| 10.8.4 | Key Developments | |
| 10.8.5 | SWOT Analysis | |
| 10.9 | Qiagen, Inc. | |
| 10.9.1 | Overview | |
| 10.9.2 | Financials | |
| 10.9.3 | Financial Summary | |
| 10.9.4 | Key Developments | |
| 10.9.5 | SWOT Analysis | |
| 10.10 | Roche Holding AG-BR | |
| 10.10.1 | Overview | |
| 10.10.2 | Financials | |
| 10.10.3 | Financial Summary | |
| 10.10.4 | Key Developments | |
| 10.10.5 | SWOT Analysis | |
| 10.11 | TEVA Pharmaceutical Industries Ltd. | |
| 10.11.1 | Overview | |
| 10.11.2 | Financials | |
| 10.11.3 | Financial Summary | |
| 10.11.4 | Key Developments | |
| 10.11.5 | SWOT Analysis | |
| 10.12 | Thermo Fisher Scientific | |
| 10.12.1 | Overview | |
| 10.12.2 | Financials | |
| 10.12.3 | Financial Summary | |
| 10.12.4 | Key Developments | |
| 10.12.5 | SWOT Analysis | |
| 10.13 | Transgenomic, Inc. | |
| 10.13.1 | Overview | |
| 10.13.2 | Financials & Financial Summary | |
| 10.13.3 | Key Developments | |
| 10.13.4 | SWOT Analysis | |
| 10.14 | Other Emerging Companies | |
| 10.14.1 | Diagnostic Test Companies | |
| 10.14.1.1 | Companiondx Reference Lab, LLC | |
| 10.14.1.2 | Mapmy Genome | |
| 10.14.1.3 | Asuragen | |
| 10.14.1.4 | 23andme | |
| 10.14.1.5 | Cnsdose | |
| 10.14.2 | Pharmaceutical Companies | |
| 10.14.2.1 | Actinium Pharmaceuticals, Inc | |
| 10.14.2.2 | Foundation Medicine | |
| 10.14.3 | Service Providers | |
| 10.14.3.1 | PGX Software LLC | |
| 10.14.3.2 | Gene Logic | |
| 10.14.3.3 | Genewiz | |
| 10.14.3.4 | Conatus Consulting, LLC | |
| 10.14.4 | Care Providers | |
| 10.14.4.1 | Gene DX | |
| 10.14.4.2 | Mayo Clinic | |
| 11 | List Of Acronyms | |
| List Of Figures | ||
| 1 | Year Consideration | |
| 2 | Market Classification & Segmentation | |
| 3 | Research Methodology | |
| 4 | Global Pharmacogenomics Market ($Billion) | |
| 5 | Global Pharmacogenomics Market Value, 2015-2022 ($Billion) | |
| 6 | Global PGX Market, By Ecosystem, 2015-2022 ($Billion) | |
| 7 | Global PGX Market Share, By Therapeutic Application, 2015-2022 ($Billion) | |
| 8 | Global Pharmacogenomics Market, By Geography-2022 | |
| 9 | Mechanism Of Action | |
| 10 | Role Of Companion Diagnostics In PGX | |
| 11 | Role Of Biomakers In PGX | |
| 12 | Role Of Molecular Diagnostics IN PGX | |
| 13 | Benefits Of PGX | |
| 14 | End-Use Applications Of PGX | |
| 15 | Market Dynamics | |
| 16 | Partnerships, Joint Ventures And Collaborations: Key Players Analysis | |
| 17 | Product Launch And Developments: Key Players Analysis | |
| 18 | Patents, Licensing, Certification And Approvals : Key Players Analysis | |
| 19 | Mergers And Acquisitions: Key Players Analysis | |
| 20 | Business Contracts And Business Expansions : Key Players Analysis | |
| 21 | Others Strategies: Key Players Analysis | |
| 22 | Porter’s Five Forces Analysis | |
| 23 | Threat Of Substitutes | |
| 24 | Threat Of New Entrants | |
| 25 | Bargaining Power Of Buyers | |
| 26 | Bargaining Power Of Suppliers | |
| 27 | Intensity Of Competitive Rivalry | |
| 28 | Roles And Responsibilities Of Healthcare Policy Makers | |
| 29 | Role Of FDA In PGX | |
| 30 | Classification Of Medical Devices | |
| 31 | Examples Of Some Common Acts | |
| 32 | Example Of Some Certifications | |
| 33 | Value Chain Analysis | |
| 34 | Example Of Some Significant Players In PGX Value Chain | |
| 35 | Generalized Process For The Microarray | |
| 36 | Different Types Of Microarrays | |
| 37 | Applications Of Microarrays | |
| 38 | Microarray- Drivers & Challenges | |
| 39 | Sequencing Technologies In PGX | |
| 40 | Sequencing - Drivers & Challenges | |
| 41 | Applications Of Sequencing | |
| 42 | NGS- Drivers & Challenges | |
| 43 | Applications Of NGS | |
| 44 | Generalized Process For PCR | |
| 45 | Different Types Of PCR | |
| 46 | PCR - Drivers & Challenges | |
| 47 | Applications Of PCR | |
| 48 | Applications Of Mass Spectrometry | |
| 49 | Applications Of Electrophoresis | |
| 50 | Overview Of PGX Ecosystem Players | |
| 51 | Global PGX Market By Ecosystem Players | |
| 52 | Global Pharmacogenomics Market, By Ecosystem , 2015-2022 ($Billion) | |
| 53 | Global PGX Ecosystem Market, By Diagnostic Tests Companies, 2015-2022 ($Billion) | |
| 54 | Global PGX Diagnostic Tests Market, By Therapeutic Applications, 2015-2022 ($Billion) | |
| 55 | Global PGX Diagnostic Tests Market, By Geography, 2015-2022 ($Billion) | |
| 56 | Diagnostic Companies- Drivers & Challenges | |
| 57 | Global PGX Ecosystem Market, By Pharmaceutical Companies, 2015-2022 ($Billion) | |
| 58 | Global PGX Pharmaceutical Market, By Therapeutic Applications, 2015-2022 ($Billion) | |
| 59 | Global PGX Pharmaceutical Market, By Geography, 2015-2022 ($Billion) | |
| 60 | Drug Development Process | |
| 61 | Role Of Pharmaceuticals Companies | |
| 62 | Pharmaceuticals Companies- Drivers & Challenges | |
| 63 | Global PGX Ecosystem Market, By Service Providers, 2015-2022 ($Billion) | |
| 64 | Global PGX Service Providers Market, By Therapeutic Applications, 2015-2022 ($Billion) | |
| 65 | Global PGX Service Providers Market, By Geography, 2015-2022 ($Billion) | |
| 66 | Three Data Drivers Of PGX Market | |
| 67 | Benefits Of Big Data | |
| 68 | Big Data Companies- Drivers & Challenges | |
| 69 | Global PGX Market By Therapeutics Applications | |
| 70 | Global PGX Market, By Theraeutics Application, 2015-2022 ($Billion) | |
| 71 | Global PGX Market By Oncology,2015-2022($Billion) | |
| 72 | Global PGX Oncology Market, By Ecosystem, 2015-2022 ($Billion) | |
| 73 | Global PGX Oncology Market, By Geography, 2015-2022 ($Billion) | |
| 74 | Types Of Cancer | |
| 75 | Oncology Market Dynamics | |
| 76 | Global PGX Market By CVD, 2015-2022 ($Billion) | |
| 77 | Global PGX CVD Market, By Ecosystem, 2015-2022 ($Billion) | |
| 78 | Global PGX CVD Market, By Geography, 2015-2022 ($Billion) | |
| 79 | Global PGX Market By CNS, 2015-2022 ($Billion) | |
| 80 | Global PGX CNS Market, By Ecosystem, 2015-2022 ($Billion) | |
| 81 | Global PGX CNS Market, By Geography, 2015-2022 ($Billion) | |
| 82 | Global PGX Market By Infectious Diseases, 2015-2022 ($Billion) | |
| 83 | Global PGX Infectious Diseases Market, By Ecosystem, 2015-2022 ($Billion) | |
| 84 | Global PGX Infectious Diseases Market, By Geography, 2015-2022 ($Billion) | |
| 85 | Global PGX Market By Other Diseases, 2015-2022 ($Billion) | |
| 86 | Global PGX Other Diseases Market, By Ecosystem, 2015-2022 ($Billion) | |
| 87 | Global PGX Other Diseases Market, By Geography, 2015-2022 ($Billion) | |
| 88 | Growth Trajectory Of PGX Market | |
| 89 | Global Pharmacogenomics Market, By Geography , 2015-2022 ($Billion) | |
| 90 | Global Pharmacogenomics Market, By Geography (2015) | |
| 91 | North American PGX Market, 2015 | |
| 92 | North American PGX Market, 2015-2022 ($Billion) | |
| 93 | North American Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) | |
| 94 | North American Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion) | |
| 95 | North American Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion) | |
| 96 | North American Market Dynamics | |
| 97 | Key Regulatory Bodies & Associations | |
| 98 | The U.S. PGX Market, 2015-2022 ($Billion) | |
| 99 | The U.S. Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion) | |
| 100 | The U.S. Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion) | |
| 101 | Canada PGX Market Dynamics | |
| 102 | European PGX Market, 2015 | |
| 103 | European PGX Market,2015-2022($Billion) | |
| 104 | European Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) | |
| 105 | European Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion) | |
| 106 | European Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion) | |
| 107 | European Market Dynamics | |
| 108 | Key Regulatory Bodies & Associations | |
| 109 | The U.K. PGX Market, 2015-2022 ($Billion) | |
| 110 | The Germany PGX Market, 2015-2022 ($Billion) | |
| 111 | APAC Country-Wise CAGR Of PGX Market | |
| 112 | APAC PGX Market, 2015-2022 ($Billion) | |
| 113 | APAC Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) | |
| 114 | APAC Pharmacogenomics MARKET,BY Ecosystem, 2015-2022 ($Billion) | |
| 115 | APAC Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion) | |
| 116 | APAC Market Dynamics | |
| 117 | The China PGX Market, 2015-2022 ($Billion) | |
| 118 | China Market Dynamics | |
| 119 | The Japan PGX Market, 2015-2022 ($Billion) | |
| 120 | The Indian PGX Market, 2015-2022 ($Billion) | |
| 121 | Indian Market Dynamics | |
| 122 | Region-Wise CAGR Of PGX Market | |
| 123 | ROW PGX Market, 2015-2022 ($Billion) | |
| 124 | ROW PGX Market, By Sub-Region, 2015-2022 ($Billion) | |
| 125 | ROW PGX Market, By Ecosystem, 2015-2022 ($Billion) | |
| 126 | ROW PGX Market, By Therapeutics, 2015-2022 ($Billion) | |
| 127 | Middle East PGX Market, 2015-2022 ($Billion) | |
| 128 | South American PGX Market, 2015-2022 ($Billion) | |
| 129 | African PGX Market, 2015-2022 ($Billion) | |
| 130 | : Abbott Laboratories, Inc.– Overall Financials, 2013-2015 ($Billion) | |
| 131 | Abbott Laboratories, Inc.- Financials By Business Segments, 2013-2015 ($Billion) | |
| 132 | Abbott Laboratories, Inc.– Financials By Geography, 2013-2015 ($Billion) | |
| 133 | Abbott Laboratories, Inc.- SWOT Analysis | |
| 134 | Affymetrix, Inc.– Overall Financials, 2013-2015 ($Million) | |
| 135 | Affymetrix, Inc.- Financials By Business Segments, 2013-2015 ($Million) | |
| 136 | Affymetrix, Inc.– Financials By Geography,2013-2015 ($Million) | |
| 137 | Affymetrix, Inc.- SWOT Analysis | |
| 138 | Assurex Health, Inc.- SWOT Analysis | |
| 139 | Astrazeneca – Overall Financials, 2013-2015 ($Billion) | |
| 140 | Astrazeneca- Financials By Business Segments, 2013-2015 ($Billion) | |
| 141 | Astrazeneca– Financials By Geography,2013-2015 ($Billion) | |
| 142 | Astrazeneca- SWOT Analysis | |
| 143 | Illumina, Inc.– Overall Financials, 2013-2015 ($Million) | |
| 144 | Illumina, Inc.- Financials By Business Segments, 2013-2015 ($Million) | |
| 145 | Illumina, Inc.– Financials By Geography, 2013-2015 ($Million) | |
| 146 | Illumina, Inc.- SWOT Analysis | |
| 147 | Laboratory Corporation Of America Holding.- Overall Financials, 2013-2015 ($Million) | |
| 148 | Laboratory Corporation Of America Holding—Financials By Business Segments, 2013-2015 ($ Million) | |
| 149 | Laboratory Corporation Of America Holding.- SWOT analysis | |
| 150 | Myriad Genetics, Inc.– Overall Financials, 2013-2015 ($Million) | |
| 151 | Myriad Genetics, Inc.– Financials By Business Segments, 2013-2015 ($Million) | |
| 152 | Myriad Genetics,INC.- SWOT Analysis | |
| 153 | Pfizer, Inc.– Overall Financials, 2013-2015 ($Billion) | |
| 154 | Pfizer,Inc. – Financials By Geography ,2013-2015 ($Billion) | |
| 155 | Pfizer, Inc.- Financials By Business Segments, 2014-2015 ($Billion) | |
| 156 | Pfizer, Inc.– Financials By Business Segment, 2013 | |
| 157 | Pfizer, Inc.- SWOT analysis | |
| 158 | Qiagen– Overall Financials, 2013-2015 ($Million) | |
| 159 | Qiagen- Financials By Business Segments, 2013-2015 ($Million) | |
| 160 | Qiagen– Financials By Geography, 2013-2015 ($Million) | |
| 161 | Qiagen- SWOT Analysis | |
| 162 | Roche Holding– Overall Financials,2013-2015 ($Billion) | |
| 163 | Roche Holding- Financials By Business Segments, 2013-2015 ($Billion) | |
| 164 | Roche Holding– Financials Of Diagnostics Division By Geography, 2013-2015 ($Billion) | |
| 165 | Roche Holding– Financials Of Pharmaceuticals,SEGMENT By Geography, 2013-2015 ($Billion) | |
| 166 | Roche Holding- SWOT Analysis | |
| 167 | TEVA Pharmaceutical Ltd.– Overall Financials, 2013-2015 ($Billion) | |
| 168 | TEVA Pharmaceutical Ltd.- Financials By Business Segments, 2013-2015 ($Billion) | |
| 169 | TEVA Pharmaceutical Ltd.– Financials By Geography, 2013-2015 ($Billion) | |
| 170 | TEVA Pharmaceutical Industries Ltd.- SWOT analysis | |
| 171 | Thermo Fisher, Inc.- Overall Financials, 2013-2015 ($Billion) | |
| 172 | Thermo Fisher, Inc.— Financials By Business Segments, 2013-2015 ($Billion) | |
| 173 | Thermo Fisher, Inc.— Financials By Geography, 2013-2015 ($Billion) | |
| 174 | Thermo Fisher Scientific, Inc.- SWOT Analysis | |
| 175 | Transgenomic, Inc.- Overall Financials,2013-2015 ($Million) | |
| 176 | Transgenomic, Inc.- Financials By Business SEGEMENTS, 2013-2015 ($Million) | |
| 177 | Transgenomic, Inc.- SWOT Analysis | |
| List of Tables | ||
| 1 | Competitive Landscape: Some Of The Key Players | |
| 2 | Recent Partnerships, Joint Ventures And Collaborations | |
| 3 | Recent Product Launch And Developments | |
| 4 | Recent Patents, Licensing, Certification And Approvals | |
| 5 | Recent Mergers And Acquisitions | |
| 6 | Recent Business Contracts And Business Expansions | |
| 7 | Recent Developments Of Other Strategies | |
| 8 | Patent Analysis Of Some Key Players | |
| 9 | Patent Analysis Of Some University/Hospital/Person | |
| 10 | Microarray- Recent Key Developments | |
| 11 | NGS- Recent Key Developments | |
| 12 | Difference Between Realt Time & Digital PCR | |
| 13 | Diagnostic Test Companies- Recent Key Developments | |
| 14 | Example Of Some Pharmacogenomic Drugs | |
| 15 | Pharmaceuticals Companies- Recent Key Developments | |
| 16 | Service Providers- Recent Key Developments | |
| 17 | Cancer- Examples Of Some Drugs | |
| 18 | Cancer- Examples Of Some Tests | |
| 19 | Oncology- Recent Key Developments | |
| 20 | CVD- Examples Of Some Drugs | |
| 21 | CVD- Examples Of Some Tests | |
| 22 | CNS- Examples Of Some Drugs | |
| 23 | CNS- Examples Of Some Tests | |
| 24 | Infectious Diseases- Examples Of Some Drugs | |
| 25 | Other Diseases- Examples Of Some Drugs | |
| 26 | North American Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) | |
| 27 | North American Pharmacogenomics Market Recent Key Dvelopments | |
| 28 | European Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) | |
| 29 | European PGX Market Recent Key Developments | |
| 30 | APAC Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) | |
| 31 | APAC Pharmacogenomics Market Recent Key Developments | |
| 32 | ROW Pharmacogenomics Market,By Sub-Region, 2015-2022 | |
| 33 | ROW Recent Key Development | |
| 34 | Abbott Laboratories, Inc. Recent Developments | |
| 35 | Affymetrix, Inc. Recent Developments | |
| 36 | Assurex Health, Inc. Recent Developments | |
| 37 | Astrazeneca Recent Developments | |
| 38 | Illumina, Inc. Recent Developments | |
| 39 | Laboratory Corporation Of America Holding Recent Developments | |
| 40 | Myriad Genetics Recent Developments | |
| 41 | Pfizer, Inc. Recent Developments | |
| 42 | Qiagen Recent Developments | |
| 43 | Roche Holding Recent Developments | |
| 44 | TEVA Pharmaceutical Industries Ltd. Recent Developments | |
| 45 | Thermo Fisher, Inc. Recent Developments | |
| 46 | Transgenomic, Inc. Recent Developments | |
The global Pharmacogenomics (PGx) market growth is gradually gaining speed as large number of government initiatives and research & development programs have been launched in the last few years.Advancement and innovation of new healthcare technologies such as next generation sequencing, high throughput screening (HTS), and Digital PCR are developing the platform for the growth of Pharmacogenomics (PGx) market. The global PGx market is expected to grow over $14.85 billion by 2022.
The market growth is propelled due to factors such as: rising usage in drug discovery processes, increasing demand for pharmacogenomics & precise drugs, technological innovation and advancement, increasing genetic disorders/abnormalities, and government support and regulations.The report has been further classified on the basis of ecosystem players, therapeutic applications, and geographical regions. Ecosystem is further segmented into: Pharmaceuticals companies, Diagnostic Companies, and Service Providers which includes Software & Healthcare database providers, Hospitals & Care Providers and Insurance Providers.
Diagnostic Test segment is holding the maximum market share and is expected to grow at 11.63% CAGR from 2016 to 2022. This is due to the increasing demand for diagnostic tests as patients are emphasizing more on pre-diagnosis treatment, increasing genetic disorders & mutational diseases, and government initiatives and investment in research and development programs among others.
In North America, existing players are integrating with new start-ups through partnerships and collaboration to capture the North American segment. North American local players are entering in other developing regions to capture more market share. Throughout the Asia-Pacific and European countries, regulatory bodies are rolling out regulations to keep a check on latest technologies.
North America is the largest contributor in the revenue generation in PGx market followed by Europe region, and is expected to grow at a high CAGR of 12.14% CAGR from 2016 to 2022. APAC region is expected to show the fastest growth globally, and is expected to grow at 18.74% CAGR from 2016 to 2022.
The APAC region is focusing more on technological development and introduction of new gene sequencing and gene mapping tools into healthcare systems to develop specific laboratory diagnostic tests.
We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.
With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.
Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.
